S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
NASDAQ:HRTX

Heron Therapeutics Stock Forecast, Price & News

$17.54
+0.04 (+0.23 %)
(As of 12/2/2020 04:35 PM ET)
Add
Compare
Today's Range
$17.14
Now: $17.54
$17.71
50-Day Range
$15.14
MA: $16.88
$18.86
52-Week Range
$9.60
Now: $17.54
$26.81
Volume966,240 shs
Average Volume1.15 million shs
Market Capitalization$1.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Heron Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400
Employees231

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$145.97 million
Book Value$3.05 per share

Profitability

Net Income$-204,750,000.00
Net Margins-216.18%

Miscellaneous

Market Cap$1.59 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$17.54
+0.04 (+0.23 %)
(As of 12/2/2020 04:35 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

How has Heron Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Heron Therapeutics' stock was trading at $13.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HRTX stock has increased by 27.4% and is now trading at $17.38.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Heron Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Heron Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Heron Therapeutics?

Wall Street analysts have given Heron Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Heron Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Heron Therapeutics
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.01. Heron Therapeutics had a negative return on equity of 65.06% and a negative net margin of 216.18%.
View Heron Therapeutics' earnings history
.

What price target have analysts set for HRTX?

8 brokers have issued 1-year price objectives for Heron Therapeutics' stock. Their forecasts range from $21.00 to $44.00. On average, they expect Heron Therapeutics' stock price to reach $32.71 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price.
View analysts' price targets for Heron Therapeutics
.

Who are some of Heron Therapeutics' key competitors?

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the following people:
  • Dr. Barry D. Quart, Chairman & CEO (Age 63, Pay $954.11k)
  • Mr. John W. Poyhonen, Pres & Chief Commercial Officer (Age 60, Pay $421.25k)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. & Director (Age 60, Pay $694.59k)
  • Mr. David L. Szekeres, Exec. VP & COO (Age 46)
  • Ms. Lisa Peraza, VP & Chief Accounting Officer (Age 44)
  • Mr. Sean T. Ristine, VP of HR (Age 50)
  • Dr. Thomas B. Ottoboni, Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences (Age 61)
  • Mr. Michael E. Mathews, Sr. VP of Pain Franchise (Age 57)
  • Dr. Chris M. Storgard, Chief Medical Officer (Age 54)

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.41%), ArrowMark Colorado Holdings LLC (5.57%), State Street Corp (4.85%), JPMorgan Chase & Co. (3.28%), Consonance Capital Management LP (2.21%) and PFM Health Sciences LP (2.06%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard and Waage Christian.
View institutional ownership trends for Heron Therapeutics
.

Which major investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., PFM Health Sciences LP, ArrowMark Colorado Holdings LLC, WINTON GROUP Ltd, Wells Fargo & Company MN, Oak Ridge Investments LLC, UBS Oconnor LLC, and Fisher Asset Management LLC.
View insider buying and selling activity for Heron Therapeutics
.

Which major investors are buying Heron Therapeutics stock?

HRTX stock was bought by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, Rothschild & Co. Asset Management US Inc., State Street Corp, Sei Investments Co., Point72 Asset Management L.P., DSAM Partners London Ltd, C WorldWide Group Holding A S, and Palisade Capital Management LLC NJ. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang, and Waage Christian.
View insider buying and selling activity for Heron Therapeutics
.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $17.38.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.58 billion and generates $145.97 million in revenue each year. The biotechnology company earns $-204,750,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Heron Therapeutics employs 231 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is www.herontx.com.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.